Trial Profile
A prophylactic efficacy trial of marzeptacog alfa for individuals with hemophilia B with inhibitors
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2016
Price :
$35
*
At a glance
- Drugs Marzeptacog alfa (Primary)
- Indications Haemophilia B
- Focus Therapeutic Use
- 15 Nov 2016 New trial record
- 03 Nov 2016 According to a Catalyst Biosciences media release, this trial is expected to initiate in 2017.